FY2025 Earnings Forecast for VKTX Issued By Leerink Partnrs

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, October 23rd. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will post earnings per share of ($2.66) for the year, down from their previous forecast of ($2.46). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.85) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($4.77) EPS and FY2028 earnings at ($1.21) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.14). The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) earnings per share.

VKTX has been the topic of a number of other research reports. Citigroup lifted their price objective on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. B. Riley upgraded Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. HC Wainwright reiterated a “buy” rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Monday, September 29th. Morgan Stanley lifted their price objective on Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, BTIG Research reiterated a “buy” rating and set a $125.00 price objective on shares of Viking Therapeutics in a research report on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $85.62.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $35.93 on Monday. The company has a market cap of $4.06 billion, a PE ratio of -16.95 and a beta of 0.64. The stock’s 50 day simple moving average is $28.44 and its 200-day simple moving average is $28.92. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.73.

Institutional Investors Weigh In On Viking Therapeutics

A number of institutional investors have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Viking Therapeutics in the second quarter valued at $46,846,000. Ameriprise Financial Inc. grew its stake in shares of Viking Therapeutics by 4.1% in the second quarter. Ameriprise Financial Inc. now owns 1,476,314 shares of the biotechnology company’s stock valued at $39,122,000 after buying an additional 58,191 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Viking Therapeutics by 27.0% in the second quarter. Raymond James Financial Inc. now owns 822,278 shares of the biotechnology company’s stock valued at $21,790,000 after buying an additional 174,887 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in shares of Viking Therapeutics by 52.8% in the second quarter. Frontier Capital Management Co. LLC now owns 638,204 shares of the biotechnology company’s stock valued at $16,912,000 after buying an additional 220,396 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Viking Therapeutics by 59.2% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 597,515 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 222,293 shares in the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.